Abstract

Correct endoproteolytic maturation of gp160 is essential for the infectivity of human immunodeficiency virus type 1. This processing of human immunodeficiency virus-1 envelope protein, gp160, into gp120 and gp41 has been attributed to the activity of the cellular subtilisin-like proprotein convertase furin. The prototypic furin recognition cleavage site is Arg-X-Arg/Lys-Arg. Arg-Arg-Arg-Arg-Arg-Arg or longer iterations of polyarginine have been shown to be competitive inhibitors of substrate cleavage by furin. Here, we tested polyarginine for inhibition of productive human immunodeficiency virus-1-infection in T-cell lines, primary peripheral blood mononuclear cells, and macrophages. We found that polyarginine inhibited significantly human immunodeficiency virus-1 replication at concentrations that were benign to cell cultures ex vivo and mice in vivo. Using a fluorogenic assay, we demonstrated that polyarginine potently inhibited substrate-specific proteolytic cleavage by furin. Moreover, we verified that authentic processing of human immunodeficiency virus-1 gp160 synthesized in human cells from an infectious human immunodeficiency virus-1 (HIV-1) molecular clone was effectively blocked by polyarginine. Taken together, our data support that inhibitors of proteolytic processing of gp160 may be useful for combating human immunodeficiency virus-1 and that polyarginine represents a lead example of such inhibitors.

Highlights

  • Human immunodeficiency virus (HIV)1/AIDS is a health problem of immense magnitude

  • Arg [9] is a potent inhibitor of furin, we investigated whether polyR would inhibit HIV-1 replication

  • When compared with mock-treated peripheral blood mononuclear cells (PBMCs), which replicated virus robustly, little to no HIV-1 production was seen in polyR-treated PBMCs (Fig. 1C)

Read more

Summary

Introduction

Human immunodeficiency virus (HIV)1/AIDS is a health problem of immense magnitude. Over 40 million individuals globally are infected with HIV. Concentrations of polyR effective against HIV-1 replication are non-toxic to cultured cells ex vivo or to mice in vivo, suggesting the utility of this compound as a novel candidate therapeutic for AIDS. 5 ϫ 105/ml MT-4 cells in a 5-ml volume of complete medium were preincubated for 15 min with polyR and AZT at the indicated concentrations and were infected with 102 or 103 RT counts/ml HIV-1 NL4-3 virus.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.